Seattle Genetics announced a potentially lucrative deal with Genentech to create more antibody drug conjugates with the latters targets. The deal calls for a $12 M payment to Seattle Genetics now with milestones that could possibly reach as high as $900 M in the future. Seattle Genetics will also be eligible for royalty payments on commercial products in the mid-single digit range.
Genetech was encouraged with the results it had seen with T-DM-1 a combination of Herceptin with a cytotoxin. Genentech is supposed to have more than 50 other candidates in its pipeline for possible antibody drug conjugation (ADC) in oncology applications.
We believe antibody-drug conjugates will play an important role in the future of cancer therapy. Genentech is committed to exploring the therapeutic potential of ADCs in a variety of hematologic malignancies and solid tumors,” said James Sabry, vice president of partnering at Genentech.
Read more in Xconomy and Fierce Biotech.
Posted by Bruce Lehr August 3rd 2010.
Comments